Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: Clinical and endometrial responses

Maturitas

Volumn 26, Issue 2, 1997, Pages 103-111

  Antoniou, G ^a,c   Kalogirou, D ^a   Karakitsos, P ^b   Antoniou, D ^a   Kalogirou, O ^a   Giannikos, L ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

hormone replacement therapy; levonorgestrel releasing intrauterine device; transdermal estradiol; transvaginal sonography; vaginal ring

Indexed keywords

ESTRADIOL; ESTROGEN; LEVONORGESTREL; PROGESTERONE;

ADULT; ARTICLE; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; INTRAVAGINAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION; TRANSVAGINAL ECHOGRAPHY;

BIOLOGY; CLINICAL RESEARCH; CLINICAL TRIALS; COMPARATIVE STUDIES; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE--THERAPEUTIC USE; CONTRACEPTIVE AGENTS, PROGESTIN--THERAPEUTIC USE; CONTRACEPTIVE AGENTS--THERAPEUTIC USE; CONTRACEPTIVE METHODS; DEVELOPED COUNTRIES; DISEASES; ENDOCRINE SYSTEM; ENDOMETRIAL EFFECTS; ENDOMETRIUM; ESTRADIOL--THERAPEUTIC USE; ESTROGENS; EUROPE; FAMILY PLANNING; GENITALIA; GENITALIA, FEMALE; GREECE; HORMONE REPLACEMENT THERAPY; HORMONES; IUD; IUD, HORMONE RELEASING; LEVONORGESTREL--THERAPEUTIC USE; MEDITERRANEAN COUNTRIES; MENOPAUSE; PHYSIOLOGY; PROGESTATIONAL HORMONES; PROGESTERONE--THERAPEUTIC USE; REPRODUCTION; RESEARCH METHODOLOGY; RESEARCH REPORT; SIGNS AND SYMPTOMS; SOUTHERN EUROPE; STUDIES; TREATMENT; UROGENITAL SYSTEM; UTERUS; VAGINAL RINGS;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVAGINAL; AGED; CLIMACTERIC; DILATATION AND CURETTAGE; DRUG THERAPY, COMBINATION; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FEMALE UROGENITAL DISEASES; HUMANS; INTRAUTERINE DEVICES; LEVONORGESTREL; MENSTRUATION; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; SAFETY; SUPPOSITORIES; UTERUS;

EID: 0031105452     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(96)01087-0     Document Type: Article

References (48)

1. [1] Iosif CS, Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand. 1984; 63: 257-260.
2. [2] Mettler L, Olsen PG. Vaginal administration of low dose oestradiol. Safety and efficiency in long-term treatment of atrophic vaginitis. Maturitas 1991; 14: 23-31.
3. [3] Mattson LA, Cullberg G, Samisioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 1982; 4: 95-102.
4. [4] Karlsson B, Granberg S, Wikland M, Ryd W, Norstrom A. Endovaginal scanning of the endometrium compared to cytology and histology in women with postmenopausal bleeding. Gynecol Oncol 1993; 50: 173-178.
5. [5] Grigoriou O, Kalovidouris A, Papadias C, Antoniou G, Antonaki V, Giannikos L Transvaginal sonography of the endometrium in women with postmenopausal bleeding. Maturitas 1996; 23: 9-14.
6. [6] Dorum A, Kristensen GB, Langebrekke A, Sornes T, Skaar O. Evaluation of endometrial thickness measured by endovaginal ultrasound in women with postmenopausal bleeding. Acta Obstet Gynecol Scand 1993; 72: 116-119.
7. [7] Bakos O, Smith P, Heimer G, Ulmsten U. Transvaginal sonography of the internal genital organs in postmenopausal women on low-dose estrogen treatment. Ultrasound Obstet Gynecol 1994; 4: 326-329.
8. [8] Grunfeld L, Walker B, Bergh PA, Sandler B, Hofmann G, Navot D. High-resolution endovaginal ultrasonography of the endometrium: a noninvasive test for endometrial adequacy. Obstet Gynecol 1991; 78: 200-204.
9. [9] Segadal E, Iversen OE. Endoscann, a new endometrial scanner. Br J Obstet Gynecol 1983; 90: 266-271.
10. [10] Hansen PK, Juge J, Roed H, Fisher-Rasmussek W, Hojgaard K. Endometrial cell sampling for cytological assessment of endometrial pathology. Acta Obstet Gynecol Scand 1986; 65: 397-399.
11. [11] Nasri MN, Shepherd JH, Setchell ME, et al. The role of vaginal scan in measurement of endometrial thickness in postmenopausal women. Br J Obstet Gynaecol 1991; 98: 470-475.
12. [12] Schmidt G, Andersson S-B, Nordle O, Johansson C-J, Gunnarsson PO. Release of 17-beta-Oestradiol from a Vaginal Ring in postmenopausal women. Pharmacokinetic Evaluation Gynecol Obstet Invest 1994; 38: 253-260.
13. [13] Stumpf PG, Maruca J, Santen RJ, Demers L. Development of a vaginal ring for achieving physiologic levels of 17β-estradiol in hypoestrogenic women. J Clin Endocrinol Metab 1982; 54: 208-210.
14. [14] Holmgren PA, Lindskog M, von Schoultz B. Vaginal rings for continuous low-dose release of oestradiol in treatment of urogenital atrophy. Maturitas 1989; 11: 55-63.
15. [15] Lindgren R, Risberg B, Hammar M, Berg G, Pryse-Davies J. Endometrial effects of transdermal estradiol/ norethisterone acetate. Maturitas 1992; 15: 71-78.
16. [16] Whitehead MI, Padwick ML, Endacott J, Pryse-Davies J. Treatment of postmenopausal women with transdermal delivery of oestradiol. Am J Obstet Gynecol 1985; 152: 1079-1084.
17. [17] Xiao B, Zhou L, Zhang X, et al. Pharmacokinetic and pharmacodynamic studies of levonororgestrel-releasing intrauterine device. Contraception 1990; 41: 353-361.
18. [18] Luukkainen T. Levonorgestrel-releasing intrauterine device. Ann New York Acad Sci 1991; 626: 43-49.
19. [19] Nilsson CG, Lahteenmaki P, Luukkainen T. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD. Contraception 1980; 21: 225-233.
20. [20] Yen SS, Martin PL, Burnier AM, et al. Circulating oestradiol, oestrone and gonadotropin levels following the administration of orally active 17b-estradiol in postmenopausal women. J Clin Endocrinol Metabol 1975; 40: 518-521.
21. [21] Van Den Bosch T, VAndendael A, Van Schoubroeck D, Wranz PAB, Lombard CJ. Combining vaginal ultrasonography and office endometrial sampling in the diagnosis of endometrial disease in postmenopausal women. Obstet Gynecol 1995; 85: 349-352.
22. [22] Goldstein SR, Nachtigall M, Snyder JR, Nachtigall L. Endometrial assessment by vaginal ultrasonography before endometrial sampling with postmenopausal bleeding. Am J Obstet Gynecol 1990; 163: 119-123.
23. [23] Granberg S, Wikland M, Karlsson B, Norstrom A, Friberg L. Endometrial thickness as measured by endovaginal sonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991; 164: 47-52.
24. [24] Fleischer AC, Kalemeris GC, Entman SS. Sonographic depiction of the endometrium during normal cycles. Ultrasound Med Biol 1986; 12: 271-277.
25. [25] Osmers R Volksen M, Rath W, Schauer A. Vaginosonography for early detection of endometrial carcinoma? Lancet 1990; 335: 1569-1571.
26. [26] Gerbaldo D, Ferraiolo A, Croce S, Trinini M and Capitano GL. Endometrial morphology after 12 months of vaginal oestriol therapy in postmenopausal women. Maturitas 1991; 13: 269-274.
27. [27] Heimer GM and Englund DE. Effects of vaginally administered oestriol on postmenopausal disorders: a cytohormonal study. Maturitas 1992; 14: 171-179.
28. [28] Martin PL, Yen SSC, Burnier AAM, Hermann H. Systemic absorption and sustained effects on vaginal estrogen creams. JAMA 1979; 242: 2699-2700.
29. [29] Smith P, Heimer G, Lindskog M, Ulmsten U. Oestradiol-releasing vaginal ring or treatment of postmenopausal urogenital atrophy. Maturitas 1993; 16: 145-154.
30. [30] Hargrove JT, Maxson WS, Colston WA, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989; 73: 606-612.
31. [31] American College of Obstetricians and Gynecologists. Hormone replacement therapy. ACOG technical bulletin no 93., American College of Obstetricians and Gynecologists, Washington DC, 1992.
32. [32] Widholm O, Vartiainen E. The absorption of conjugated oestrogen and sodium oestrone sulfate from the vagina. Ann Chir Gynaecol Fenn 1974; 63: 186-190.
33. [33] Luisi M, Franchi F, Kicovic PM. A group-comparative study of effects of Ovestin cream versus Premarin cream in postmenopausal women with vaginal atrophy. Maturitas 1980; 2: 309-311.
34. [34] Whitehead MI, Townsend PT, Gill DK, Collins WP, Campbell S. Absorption and metabolism of oral progesterone. BMJ 1980; 280: 825-929.
35. [35] Norman TR, Morse CA, Dennerstein L. Comparative bioavailability of orally and vaginally administered progesterone. Fertil Steril 1991; 56: 1034-1039.
36. [36] Miles RA, Press MF, Paulson RJ, Dahmoush L, Lobo RA, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994; 62: 485-490.
37. [37] Archer DF, Fahy GE, Vinierga-Sibal A, Anderson FD, Snipes W, Foldesy RG. Initial and steady-state pharmacokinetics of a vaginally administered formulation on progesterone. Am J Obstet Gynecol 1995; 173: 471-478.
38. [38] Wiklund I, Holst J, Karlberg J. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 1992; 14: 211-224.
39. [39] Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991; 78: 991-995.
40. [40] Ross AH, Boyd ME, Colgan TJ, Ferenczy A, Fugere P, Lorrain J. Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding pattterns and endometrial histology. Obstet Gynecol 1993; 82: 773-779.
41. [41] Smith P, Heimer G, Lindskog M, Ulmsten U. Estradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 1993; 16: 145-154.
42. [42] Key TJA, Pike MG. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988; 57: 205-212.
43. [43] Boman K. Influence of oestrogen on growth of endometrial carcinoma. Anticancer Res 1990; 10: 173-176.
44. [44] Andersson K, Mattson LA, Rybo G, Stadberg E. Intrauterine release of levonorgestrel - a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 79: 963-967.
45. [45] Raudaskoski TH, Lathi EI, Kauppila AJ, Apaja-Sarkkinen MA, Laatikainen TJ. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: Clinical and endometrial responses. Am J Obstet Gynecol 1995; 172: 114-119.
46. [46] Staland B. Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas 1981; 3: 145-156.
47. [47] Mattson LA, Cullberg G, Samisioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 1982; 4: 95-102.
48. [48] Nilsson CG, Lahteenmaki P, Luukkainen T. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD. Contraception 1980; 21: 225-233.